News06.03.2025
DvH Ventures backs HelloBetter to accelerate international expansion
Berlin, Germany - 06 March 2025 - HelloBetter, a leader in digital mental health care, today announced that it has secured over €6 million in cash and media-for-equity. The round was led by Mutuelles Impact - managed by XAnge - with participation from DvH Ventures, MMV, HealthCap and Expon. This latest capital injection brings the total funding secured by the company to €31 million. The funding round follows HelloBetter's recent announcement of €3 million in non-dilutive funding for the development of an AI-powered mental wellness solution.

Strategic Expansion into French Market
A key priority for HelloBetter in 2025 is to enter the French market. Mutuelles Impact, a €95 million social and environmental impact fund dedicated to health and medico-social initiatives and managed by XAnge - which led this round of financing - is primarily funded by 65 French Mutuelles, based on an original idea by La Mutualité Francaise - complementary health insurance providers that complement the state's social security coverage. HelloBetter intends to use this strategic link to launch pilots and establish long-term partnerships, the company's first outside the DACH region. The partnerships with the mutuals will make HelloBetter's digital mental health solutions widely available to their members. In addition to its currently marketed portfolio of digital therapeutics, HelloBetter will also offer its new innovative AI products to these partners. In addition, HelloBetter will also seek approval from the HAS to secure national reimbursement in France.
"This funding will enable us to do three things: become a household name for mental health in Germany, launch new, innovative products and, with the support of XAnge and its 65 Mutuelles partners, bring our proven digital mental health solutions to the French market.”
Building on proven success
HelloBetter's expansion plans build on its strong foundation in evidence-based digital therapeutics. Today, the company offers ten online therapy programmes for various mental health conditions. Six of these programmes have been approved by the German Federal Institute for Drugs and Medical Devices (BfArM) and are therefore part of the standard of care in the German healthcare system. More than 120,000 patients have already benefited from these programmes, demonstrating both the accessibility and effectiveness of the mental health support offered by HelloBetter.
"As the global political climate becomes more hostile, conflicts escalate, and social media becomes a breeding ground for unchecked disinformation, the strain on people's mental health is probably greater than it has been in decades," continues Hannes Klöpper. "People need fast, accessible and affordable support, and our aim is to provide just that - on a global scale. We are committed to becoming a leader in digital mental health, offering solutions that enable everyone to find support whenever and wherever they need it."
About HelloBetter
HelloBetter is a leader in the field of digital mental health care and a global pioneer in digital mental health research. Founded in 2015 by Prof. Dr. David Ebert, Dr. Hanne Horvath, and Dr. Elena Heber, the company has established itself as an innovation leader in digital therapeutics. HelloBetter offers ten online therapy programmes, addressing both common mental health conditions such as depression, insomnia, and panic disorders, as well as underserved conditions including vaginismus and chronic pain. Six of these programmes have received approval from the German Federal Institute for Drugs and Medical Devices (BfArM) and are fully integrated into Germany's standard healthcare system, available free of charge to all publicly insured adults as prescription digital therapeutics (PDTx), also known as DiGA. In 2022, HelloBetter expanded internationally with the launch of HelloGina in the US market, offering specialised sexual wellness support for individuals with vaginismus. The company's innovation and potential were further validated in early 2023 with the prestigious 'breakthrough device designation' for Digital Therapeutic to treat Panic Disorder from the FDA. HelloBetter's scientific excellence is demonstrated through its unparalleled evidence base, comprising 30 randomised controlled trials on its commercial products, with the majority published in peer-reviewed journals. Headquartered across Berlin, Potsdam, and Hamburg, HelloBetter employs over 150 professionals dedicated to advancing digital mental healthcare. For more information, visit https://hellobetter.de/.